Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

Oculis announced a presentation at Clinical Trials at the Summit 2026 on its investigational drug Privosegtor, a neuroprotective therapy candidate for optic neuritis. The company highlighted positive Phase 2 ACUITY trial results and regulatory milestones including FDA Breakthrough Therapy designation and EMA PRIME designation, as it advances the PIONEER registrational program.